Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammet Özbilen has a total of 189 co-authors. Here are the top co-authors by number of shared publications:

  • Yasemin Kaya

    Department of Internal Medicine, School of Medicine, Ordu University, Ordu 52200, Türkiye

    6 shared publications
  • Yasemin Kaya

    Ordu University School of Medicine, Internal Medicine, Ordu, Turkey

    5 shared publications
  • Ahmet Kaya

    Özbilen: Assistant Professor, Ordu University, Faculty of Medicine, Department of Internal Medicine. Bostan: Professor, Ordu University, Faculty of Health Sciences, Department of Health Management. Kaya: Professor, Ordu University, Faculty of Medicine, Department of Cardiology. Kaya: Associate Professor, Ordu University, Faculty of Medicine, Department of Internal Medicine. Kurt: Assistant Professor, Ordu University, Faculty of Medicine, Department of Infectious Diseases

    4 shared publications
  • Seçkin Dereli

    Department of Cardiology Ordu University Faculty of Medicine Ordu Turkey

    3 shared publications
  • Adil Bayramoğlu

    Department of Cardiology Faculty of Medicine Inonu University Malatya Turkey

    2 shared publications
  • Harun Düğeroğlu

    2 shared publications

Latest Publications

  • Open Access

    Comment on Inghilleri, G.; Franchini, M. Hypophosphatemia in Patients Receiving Intravenous Iron Supplementation for Iron-Deficiency Anemia: A Narrative Review. J. Clin. Med. 2026, 15, 4748

    by Ceren Çevik, Nur Düzen Oflas, Kamil Konur, Gökhan Tazegül, Nurhayat Özkan Sevencan, Muhammet Özbilen

    We read with great interest the narrative review by Inghilleri and Franchini about hypophosphatemia in patients receiving intravenous iron supplementation for iron-deficiency anemia


  • Open Access

    Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study)

    by Ali Kirik, Hilmi Erdem Sumbul, Nizameddin Koca, Türkan Paşalı Kilit, Sibel Demiral Sezer, Emine Binnetoglu, Eşref Araç, İhsan Solmaz, Hacer Şen, İbrahim Demirci, et al.

    Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.


  • Open Access

    Patterns of Ferric Carboxymaltose Use, Demographic Characteristics and Departmental Preferences

    by Muhammet Özbilen

    Ferric carboxymaltose (FCM), a common intravenous iron therapy for iron deficiency anemia, is useful but may cause side effects depending on age, gender, and hospital unit. This study examines the use trends of FCM across several medical departments, emphasizing demographic and ward-specific differences. Patients who received FCM treatment at a training and research hospital were analyzed retrospectively and cross-sectionally throughout a 24-month period from January 2021 to December 2022. Accordingly, the drug exemption reports were assessed to determine which departments favoured ferric carboxymaltose in which clinical conditions for patients above 18 years of age. The sample consisted of 1866 patients. The median age was 49 years (18–97). Women accounted for 74.6% of cases, with a median age of 44 years, while men represented 25.4% ($$\chi^2=452$$, $$df=1$$, $p<0.001$), with a higher median age of 67.5 years ($$U=161327$$, $$p<0.001$$). The departments that most commonly granted FCM drug exemption reports were internal medicine (41.7%), hematology (25.2%), and cardiology (13.9%) ($$\chi^2=1665$$, $$df=6$$, $$p<0.001$$). Administration locations were 78.3% outpatient clinics, 18.3% normal wards, and 3.4% intensive care units (ICU) ($$\chi^2=1759$$, $$df=2$$, $$p<0.001$$). In contrast to other departments, cardiovascular surgery treated predominantly male patients (80.6%). Obstetrics and gynecology and cardiovascular surgery predominantly administered FCM to inpatients. The cardiology department administered 71.8% of FCM treatments in ICUs. Ferric carboxymaltose exhibits department-specific variations based on gender and its administration to outpatients or inpatients, offering significant insights for all administrative procedures related to this medicine.

  • Open Access

    Beyond anemia: a comprehensive analysis of iron deficiency symptoms in women and their correlation with biomarkers

    by Muhammet Özbilen, Yasemin Kaya

    Iron deficiency, the most widespread micronutrient deficiency globally, is especially common among women and seriously impacts their health considerably. The symptom spectrum in non-anemic iron deficiency (NAID) is less well described than in anemic forms. The aim of this study was to demonstrate the diversity and frequency of symptoms in NAID and compare with anemic cases and explore the association of symptoms with biomarkers. This retrospective and cross-sectional study was conducted on female patients at a university hospital. Patients admitted to the iron deficiency outpatient clinic between March 2021 and August 2022 were analyzed. Patients aged 18 years and older with iron deficiency (ferritin < 30 mcg/L) were included. Iron parameters, hemoglobin levels, and symptoms were included into the dataset, and these independent variables were compared between patient groups categorized as NAID and iron deficiency anemia (IDA). The study sample consisted of 239 patients. The frequencies of IDA and NAID were 70.3% (n = 168) and 29.7% (n = 71), respectively. Forty-one distinct symptoms or symptom groups were documented, ranging from neuropsychiatric to gastrointestinal manifestations. The mean number of symptoms per person was 16.5 (7.03). The top ten most common symptoms were weakness (87.03%), fatigue (82.43%), easy fatigability (78.66%), amnesia (72.38%), feeling cold (71.55%), alopecia (70.29%), cold intolerance (69.04%), sleep problems (66.53%), nervosity (63.18%), and cold foot (59.83%). The IDA group had more diverse symptoms than the NAID group (P <.05). Most of the forty-one symptoms or symptom groups were similar in frequency in the IDA and NAID groups. Only palpitations, cold intolerance, easy fatigability, and unclassifiable group differed between the groups (P <.05). The highest correlation between iron parameters and symptom diversity was transferrin saturation (TSAT) (r=-.229, P <.001). All but three of the positive symptoms showed TSAT levels below 8%. This study confirms that anemia is not a prerequisite for the majority of iron deficiency symptoms, which are common in non-anemic women. TSAT demonstrates a robust correlation, underscoring its potential as an early diagnostic biomarker. Clinicians must acknowledge various non-specific symptoms irrespective of anemia. Additional research is required to corroborate findings and investigate symptom mechanisms and treatments.


  • Open Access

    Investigation of Physicians' Attitudes Towards Artificial Intelligence: A Qualitative Study (Preprint)

    by Murat Özdede, Muhammet Özbilen, Zeynep Pelin Polat, Gizem Zorlu Görgülügil, İbrahim Hakkı Tezci

    BACKGROUND The rapid adoption of artificial intelligence (AI) in healthcare emphasizes the importance of assessing healthcare professionals' attitudes towards this technology. OBJECTIVE The aim of this study was to develop and validate a reliable and comprehensive Artificial Intelligence Attitude Scale (AIAS) with a number of subscales for physicians. METHODS This qualitative study was conducted cross-sectionally between January and March 2024. For this investigation, three stages were identified. The first stage involves the development of an item pool pertaining to artificial intelligence and informatics. The next stage entails administering the generated items to a primary sample of physicians using a 5-point Likert questionnaire, followed by conducting explanatory and confirmatory factor analyses on the acquired data. The last stage consists of distributing the newly established scale to a secondary sample of physicians, assessing the scores across the scale's subcategories, and investigating their variations concerning certain independent variables. RESULTS A questionnaire comprising 47 items was distributed to clinicians following an expert evaluation. The initial sample consisted of 239 participants who completed the questionnaire. After the outliers were eliminated, the results of 198 participants were analyzed. Exploratory factor analysis (EFA) identified a three-factor structure (Belief, Knowledge, Practice) with robust factor loadings (0.64 and above) and an overall explained variance of 62.64%. The data set was considered appropriate for EFA according to the Kaiser-Mayer-Olkin (KMO) (0.91) and Bartlett's test (χ2=712.63, P<.001), and the principal axis factoring method with varimax rotation was utilized due to the lack of multivariate normality. After confirmatory factor analysis (CFA), the scale's (AIAS) final version comprised 26 items and three subscales emerged: belief (11 items), knowledge (7 items) and practice (8 items). All t values of the loadings of these subscales were significant (P<.001). The AIAS showed strong internal consistency (Cronbach's alpha >0.88 and composite reliability >0.70 for all subscales) and acceptable model fit indices in CFA. The AIAS was administered to a second new sample of 509 physicians in the concluding stage of the study, and 441 responses from this sample were considered to be valid. Findings revealed that physicians generally held positive beliefs about AI (mean belief score: 37.58 ± 9.22), but knowledge (18.71 ± 5.81) and practice (11.31 ± 3.7) scores remained lower. Male physicians (P<.001), those in academic roles (P<.001) and those working in private hospitals (P<.05) generally reported higher scores on some subscales, while higher workload was associated with lower practice scores (P<.05). CONCLUSIONS The AIAS provides a robust tool to assess attitudes towards AI in healthcare. While physicians recognize the potential benefits of AI, practical adoption requires targeted training, improved infrastructure and addressing ethical challenges.

  • Ferric Carboxymaltose-mediated Methemoglobinemia

    by Muhammet Özbilen, Şeyda Tuba Savrun, Ali Aygün, Yasemin Kaya

    Background: Methemoglobinemia is a life-threatening disorder, with levels above 1 percent considered abnormal and typically resulting from drug or toxic substance exposure. Case Presentation: In this study, we describe a case of a 43-year-old woman with a long-standing complaint of fatigue. Iron deficiency anemia was diagnosed based on the blood test findings of hemoglobin of 101 g/L, mean red blood cell volume of 75 fL, ferritin of 2.81 ug/L, transferrin saturation of 4.3 percent, and C-reactive protein of 0.6 mg/L. As a preferred treatment option, 1000 mg ferric carboxymaltose on two distinct days was preferred. After administering the first dose of the medication, we noticed incidentally that methemoglobin levels increased to 2.3%. When venous blood gas was repeated before and after administration of the second dose of the drug, methemoglobin levels were found to be 0.8% and 1.8%, respectively. There was no change in vital signs in both two dosages, and she only suffered a temporary sore throat. Her anemia improved with intravenous iron therapy, and she is currently being followed in our clinic. Discussion: No case or research reporting an increase in methemoglobin levels following oral and/or intravenous treatment to patients with iron deficiency anemia has been found in the literature. Therefore, this is the first contribution to the existing literature.


  • Coexistence of multiple causes in patients with iron deficiency.

    by M Özbilen

    The etiology of disorders may be attributable to multiple causal factors simultaneously. This study sought to investigate how frequently, and which causes coexist in patients with iron deficiency. All patients who applied to the Iron Deficiency Outpatient Clinic between January and December 2021 were included in this cross-sectional study. The causes of iron deficiency were extracted from patient files. Analyses were conducted on the entire population as well as three subgroups: women of reproductive age, postmenopausal women, and males. Numbers and frequencies of causes of iron deficiency were calculated. The subgroups were compared using the Jamovi software. The study sample comprised a total of 331 patients. Women of reproductive age were the majority of patients admitted to the clinic (86.7%, n=287). Men represented 6.3% of the sample (n=21), and postmenopausal women accounted for 7.0% (n=23). The mean ages were 37.6±9.05, 49.2±15.49 and 57.8±10.84 years, respectively. The overall sample's rate of multiple iron deficiency causes coexisting was 33.5% (n=111) and the subgroups showed similar frequencies for the coexistence of multiple causes. Statistically, the number of simultaneous multiple causes varied between subgroups (χ2=118, df=10, p<0.001). Heavy menstrual bleeding and nonsteroidal anti-inflammatory drug use were the most common dual causes of multiple coexisting conditions (n=46, 41.4%). In terms of the number of causes, the coexistence of two causes of iron deficiency in women was notable, whereas the coexistence of three causes in males was remarkable. Furthermore, it has been found that some patients have up to five coexisting causes of iron deficiency. Some iron deficiency causes may coexist, and this must be taken into account for the effective management of iron deficiency.


  • Open Access

    Is Hyperferritinemia Reliable in Determining the Severity of COVID-19 in Older Patients?

    by Muhammet Özbi̇lEn, Şeyda Tuba Savrun, Celali Kurt, Yeliz Kaşko Arici

    Aim: To determine whether ferritin levels among elderly patients inflicted with Covid-19 are superior to several types of disease severity indicators. Methods: A retrospective and cross-sectional analysis was conducted on patients who were admitted to the emergency department of Ordu University Training and Research Hospital between September 2020 and January 2021, with a suspected or confirmed diagnosis of Covid-19. Patients had to be 18 years of age or older and have a glomerular filtration rate greater than 30 ml/min/1.73 m2 in order to meet the basic inclusion criteria. In addition, the data pertaining to the patients’ chronic diseases, mortality status, hemogram, blood gas, ferritin, c-reactive protein, and vital signs were recorded alongside the information regarding the tests and examinations conducted for the diagnosis of Covid-19. The data set is divided into two parts: <65 years ≥65 years. Results: Four hundred sixteen patients were identified as meeting the criteria for the study. Out of the total number of patients, 321 were under the age of 65, while 95 were 65 years of age or older. The under-65 group’s mean age was 42.50±12.73 while the older group was 77.89±7.34 years. The mean ferritin of patients 65 and older (249.59±261.45 ng/mL) was significantly more than the patients under 65 (169.76±210.44 ng/mL) (p=0.001). Only mortality differed between older and younger patients (p=0.049). The AUC value of ferritin in older patients was 0.700 (95% CI, 0.482-0.919), and the cut-off value was 231.55 ng/mL in the mortal group (sensitivity=66.7%, specificity=67.4%). Only ferritin levels were significant in older patients’ AUC scores of mortality stats among the other biomedical markers. Conclusions: Some well-known severe disease blood markers, including c-reactive protein, are not as significant as ferritin in older patient mortality ROC curve analyses. Ferritin may be the strongest mortality predictor in older Covid-19 patients.